A multi-centre, open label, single arm, Ph IV, interventional study to evaluate the efficacy of Erlotinib following 4 cycles of platinum-based chemotherapy in pts with locally advanced or metastatic NSCLC who have not experienced disease progression or unacceptable toxicity during chemotherapy.

Trial Profile

A multi-centre, open label, single arm, Ph IV, interventional study to evaluate the efficacy of Erlotinib following 4 cycles of platinum-based chemotherapy in pts with locally advanced or metastatic NSCLC who have not experienced disease progression or unacceptable toxicity during chemotherapy.

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 Nov 2010

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 05 Nov 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top